You just read:

Merrimack Stockholders Approve Sale of ONIVYDE® and Generic Version of DOXIL® to Ipsen for Up to $1.025 Billion

News provided by

Merrimack Pharmaceuticals, Inc.

Mar 30, 2017, 12:00 ET